Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Addressing barriers to clinical trial participation among underserved minority patients

Inimfon Jackson • 13 Dec 2024
SABCS 2024
Breast Cancer

Inimfon Jackson, MD, PhD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of a survey conducted among underserved patients with cancer to identify barriers and facilitators of clinical trial participation. Key barriers included out-of-pocket costs and frequent testing, while facilitators included language assistance and financial support. Most patients valued their physician’s opinion and expressed willingness to join trials, particularly as first-line treatment, highlighting opportunities for targeted interventions. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Inimfon Jackson

Addressing access barriers and guideline-concordant breast cancer care
1:07
Addressing access barriers and guideline-concordant breast cancer care
Inimfon Jackson • 10 Dec 2025
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
2:28
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
Inimfon Jackson • 10 Dec 2025
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
1:53
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
Inimfon Jackson • 30 May 2025
Navigating discussions with patients who have high-risk genomics but are reluctant about chemo
0:57
Navigating discussions with patients who have high-risk genomics but are reluctant about chemo
Inimfon Jackson • 30 May 2025

Related Videos

How can genomic assays guide treatment in HR+/HER2- breast cancer?
1:26
How can genomic assays guide treatment in HR+/HER2- breast cancer?
Kevin Kalinsky • 25 Oct 2026
Disease control and patient-reported quality of life in the ASCENT-04 trial
0:56
Disease control and patient-reported quality of life in the ASCENT-04 trial
Kevin Kalinsky • 25 Oct 2026
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
1:02
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
Kevin Kalinsky • 25 Oct 2026
Treating triple negative early breast cancer after optimal neoadjuvant therapy
2:24
Treating triple negative early breast cancer after optimal neoadjuvant therapy
Joana Ribeiro • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals